keyword
MENU ▼
Read by QxMD icon Read
search

Radioiodine treatment

keyword
https://www.readbyqxmd.com/read/28076008/pictorial-review-of-false-positive-results-on-radioiodine-scintigrams-of-patients-with-differentiated-thyroid-cancer
#1
Amy V Chudgar, Jagruti C Shah
Radioiodine has served an important role in the diagnostic workup and treatment of patients with differentiated thyroid cancer for more than 6 decades. The interpretation of radioiodine scintigraphic studies should be performed in conjunction with a comprehensive history, histopathologic correlation, and pertinent laboratory values, as well as correlation with available anatomic images and the findings from physical examination. A thorough understanding of the physiology and biodistribution of radioiodine is critical when interpreting radioiodine scintigraphic studies to avoid misinterpretation of physiologic and nonthyroid pathologic variants as thyroid cancer metastases...
January 2017: Radiographics: a Review Publication of the Radiological Society of North America, Inc
https://www.readbyqxmd.com/read/28025634/regional-variation-across-canadian-centers-in-radioiodine-administration-for-thyroid-remnant-ablation-in-well-differentiated-thyroid-cancer-diagnosed-in-2000-2010
#2
I Rachinsky, M Rajaraman, W D Leslie, A Zahedi, C Jefford, A McGibbon, J E M Young, K A Pathak, M Badreddine, S De Brabandere, H Fong, S Van Uum
Background. Use of radioactive iodine (RAI) ablation has been reported to vary significantly between studies. We explored variation in RAI ablation care patterns between seven thyroid cancer treatment centers in Canada. Methods. The Canadian Collaborative Network for Cancer of the Thyroid (CANNECT) is a collaborative registry to describe and analyze patterns of care for thyroid cancer. We analyzed data from seven participating centers on RAI ablation in patients diagnosed with well-differentiated (papillary and follicular) thyroid cancer between 2000 and 2010...
2016: Journal of Thyroid Research
https://www.readbyqxmd.com/read/28002173/higher-preablative-serum-thyroid-stimulating-hormone-level-predicts-radioiodine-ablation-effectiveness-in-patients-with-differentiated-thyroid-carcinoma
#3
Ismaheel O Lawal, Nozipho E Nyakale, Lerwine M Harry, Thabo Lengana, Neo P Mokgoro, Mariza Vorster, Mike M Sathekge
INTRODUCTION: Radioiodine ablation of remnant thyroid tissue is an important adjuvant therapy of differentiated thyroid carcinoma (DTC) after thyroidectomy. Elevated serum thyroid-stimulating hormone (TSH) level is necessary for successful ablation. The optimum level of serum TSH level necessary for successful radioiodine ablation of well-DTC is, however, yet to be defined. We aimed to determine whether higher serum TSH level will result in a better rate of complete ablation of well-DTC using iodine-131 (I) following initial thyroidectomy...
December 20, 2016: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/27994875/management-of-metastatic-thyroid-cancer-in-pregnancy-risk-and-uncertainty
#4
Christopher W Rowe, Kirsten Murray, Andrew Woods, Sandeep Gupta, Roger Smith, Katie Wynne
: Metastatic thyroid cancer is an uncommon condition to be present at the time of pregnancy, but presents a challenging paradigm of care. Clinicians must balance the competing interests of long-term maternal health, best achieved by iatrogenic hyperthyroidism, regular radioiodine therapy and avoidance of dietary iodine, against the priority to care for the developing foetus, with inevitable compromise. Additionally, epidemiological and cellular data support the role of oestrogen as a growth factor for benign and malignant thyrocytes, although communicating the magnitude of this risk to patients and caregivers, as well as the uncertain impact of any pregnancy on long-term prognosis, remains challenging...
2016: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/27988801/measuring-the-actual-i-131-thyroid-uptake-curve-with-a-collar-detector-system-a-feasibility-study
#5
Peter Brinks, Koen Van Gils, Ellen Kranenborg, Jules Lavalaye, Dennis B M Dickerscheid, Jan B A Habraken
Radionuclide therapy using I-131 is commonly used for the treatment of benign thyroid diseases. The therapeutic dose to be administered is calculated based on the type of disease, the volume of the thyroid, and the measured uptake percentage. This methodology assumes a similar biological half-life of iodine, whereas in reality a large variation in biological half-life is observed. More knowledge about the actual biological half-life of iodine for individual patients will improve the quantification of the delivered radiation dose during radioiodine therapy and could aid the evaluation of the success of the therapy...
December 17, 2016: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27984538/clinical-outcomes-of-low-dose-and-high-dose-postoperative-radioiodine-therapy-in-patients-with-intermediate-risk-differentiated-thyroid-cancer
#6
Ju Hye Jeong, Eun Jung Kong, Shin Young Jeong, Sang-Woo Lee, Ihn Ho Cho, Kyung Ah Chun, Jaetae Lee, Byeong-Cheol Ahn
PURPOSE: Recent studies have suggested that a low dose (LD) of radioiodine (RAI) is sufficient to treat differentiated thyroid cancer (DTC) even in patients with intermediate risk. However, these studies evaluated the efficacy of RAI therapy, irrespective of the results of the whole-body scan (WBS). The aim of the present study was to evaluate the response to LD and high-dose (HD) RAI therapy using two different criteria (with and without WBS results) and the reclassification system according to the revised 2015 guidelines of the American Thyroid Association in Korean intermediate-risk DTC patients...
December 14, 2016: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/27973140/the-evpi-of-treatment-strategies-for-radioiodine-refractory-differentiated-thyroid-cancer
#7
W Huang, L Chen, J Ting, V Cao, H Sung, M Yokokura, L Wilson
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27940017/honokiol-a-potential-therapeutic-agent-induces-cell-cycle-arrest-and-program-cell-death-in-vitro-and-in-vivo-in-human-thyroid-cancer-cells
#8
Chieh-Hsiang Lu, Shu-Hsin Chen, Yi-Sheng Chang, Yi-Wen Liu, Jin-Yi Wu, Yun-Ping Lim, Hui-I Yu, Ying-Ray Lee
Thyroid cancer is the most common endocrine malignancy, the global incidence rate of which is rapidly rising. Surgery and radioiodine therapies are common and effective treatments only for nonmetastasized primary tumors. Therefore, effective treatment modalities are imperative for patients with radioiodine-resistant thyroid cancer. Honokiol, a biophenolic compound derived from Magnolia spp., has been shown have diverse biological and pharmacological activities, including anti-inflammatory, antioxidative, antiangiogenic, and anticancer properties...
January 2017: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/27929713/postoperative-thyroglobulin-and-neck-ultrasound-in-the-risk-re-stratification-and-decision-to-perform-131-i-ablation
#9
Antonio Matrone, Carla Gambale, Paolo Piaggi, David Viola, Carlotta Giani, Laura Agate, Valeria Bottici, Francesca Bianchi, Gabriele Materazzi, Paolo Vitti, Eleonora Molinaro, Rossella Elisei
CONTEXT: For many years, total thyroidectomy (TTx) and radioiodine remnant ablation (RRA) represented the initial treatment of differentiated thyroid cancer (DTC). There is currently much debate surrounding the clinical impact of RRA, particularly in low (LR) and intermediate (IR) risk DTC. OBJECTIVE: To evaluate the role of postoperative High-Sensitive Thyroglobulin on L-thyroxine (LT4-HSTg) and postoperative neck ultrasound (nUS) in risk re-stratification and decision to perform RRA...
December 8, 2016: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/27909769/evaluation-of-131-i-scintigraphy-and-stimulated-thyroglobulin-levels-in-the-follow-up-of-patients-with-dtc-a-retrospective-analysis-of-1420-patients
#10
Jose Manuel Gonzalez Carvalho, Dennis Görlich, Otmar Schober, Christian Wenning, Burkhard Riemann, Frederik Anton Verburg, Alexis Vrachimis
AIM: To study the clinical yield of diagnostic whole body (131)I scintigraphy (DxWBS) in the follow-up of differentiated thyroid carcinoma (DTC) patients in relation to stimulated thyroglobulin (sTg) in the initial post-ablation setting, as well as in the setting of repeated monitoring in course of further DTC follow-up. METHODS: Data of 1420 thyroidectomized and radioiodine remnant-ablated DTC patients following a well-defined therapy and standardized follow-up protocol were evaluated...
December 1, 2016: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27908147/strategies-for-ct-tissue-segmentation-for-monte-carlo-calculations-in-nuclear-medicine-dosimetry
#11
P E N Braad, T Andersen, S B Hansen, P F Høilund-Carlsen
PURPOSE: CT images are used for patient specific Monte Carlo treatment planning in radionuclide therapy. The authors investigated the impact of tissue classification, CT image segmentation, and CT errors on Monte Carlo calculated absorbed dose estimates in nuclear medicine. METHODS: CT errors as a function of patient size, CT reconstruction, and tube current modulation methods were assessed in a phantom experiment on a clinical CT system. The impact of tissue segmentation methods and CT number variations on EGSnrc Monte Carlo calculated absorbed dose distributions was assessed for (99m)Tc and (131)I in the ICRP/ICRU male phantom and in a patient PET/CT-scanned with (124)I prior to radioiodine therapy...
December 2016: Medical Physics
https://www.readbyqxmd.com/read/27902601/time-course-of-graves-orbitopathy-after-total-thyroidectomy-and-radioiodine-therapy-for-thyroid-cancer
#12
Camille Louvet, Annamaria De Bellis, Bruno Pereira, Claire Bournaud, Antony Kelly, Salwan Maqdasy, Beatrice Roche, Francoise Desbiez, Francoise Borson-Chazot, Igor Tauveron, Marie Batisse-Lignier
The risk of cancer is relatively higher in Graves' patients presenting simultaneously with thyroid nodules. Radioiodine (RAI) therapy recommended in high-risk differentiated thyroid carcinoma may be associated with worsening of a pre-existing Graves' orbitopathy (GO) or developing a new onset. The impact of RAI therapy in patients with differentiated thyroid cancer on the course of a pre-exisiting GO has not been specifically investigated.The aim of this study is to assess the influence of RAI treatment administered for differentiated thyroid cancer on the course of a pre-existing GO...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27893690/prognosis-of-papillary-thyroid-carcinoma-in-elderly-patients-after-thyroid-resection-a-retrospective-cohort-analysis
#13
Nathalie Chereau, Christophe Trésallet, Severine Noullet, Gaelle Godiris-Petit, Frederique Tissier, Laurence Leenhardt, Fabrice Menegaux
The size of the elderly population and the incidence of papillary thyroid carcinoma (PTC) in this group appear to be rapidly increasing, although published information based on more detailed older age groupings are lacking.This study aimed to determine the clinical features and outcomes of elderly patients in PTC.All consecutive patients who received surgery for PTC in our Department from 1978 to 2014 were included. We compared 3 patient groups: young (<65 years), older (65-75 years), and very old patients (>75 years)...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27884196/palliative-treatment-of-pelvic-bone-tumors-using-radioiodine-125-i-brachytherapy
#14
Chongren Wang, Zhengqi Chen, Wei Sun, Yisilamu Yasin, Chuanyin Zhang, Xiaojun Ma, Jian Chen, Jiakang Shen, Yingqi Hua, Zhengdong Cai
BACKGROUND: Complete resection of pelvic bone tumors, especially recurrent and metastatic ones, is often impossible to achieve using conventional surgery. This study aimed to assess the benefits and adverse effects of computed tomography (CT)-guided radioiodine ((125)I) brachytherapy for inoperable recurrent and metastatic bone tumors of the pelvis. METHODS: This was a retrospective study of 22 patients with confirmed pelvic bone tumors (10 females and 12 males; 15-84 years; 21 with primary pelvic tumor and one with pelvic metastasis)...
November 25, 2016: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27881018/a-different-prognostic-value-of-brafv600e-mutation-positivity-in-different-age-groups-of-patients-with-papillary-thyroid-cancer
#15
E Takacsova, R Kralik, I Waczulikova, K Zavodna, J Kausitz
The aim of retrospective single-center study was to assess the prognostic value of BRAFV600E mutation positivity (BRAFV600E+) on disease persistence/recurrence in patients with papillary thyroid cancer (PTC). A total of 199 patients having had initial surgery with neck dissection in our hospital between 6/2009-6/2012 were included in the cohort. Excluded were patients with unifocal microcarcinoma ≤1cm. BRAFV600E mutation was tested from formalin-fixed paraffin-embedded surgicaly removed tumors. All included patients were postoperatively treated with radioiodine...
November 24, 2016: Neoplasma
https://www.readbyqxmd.com/read/27867395/radioactive-iodine-administration-is-associated-with-persistent-related-symptoms-in-patients-with-differentiated-thyroid-cancer
#16
Pablo Florenzano, Francisco J Guarda, Rodrigo Jaimovich, Nicolás Droppelmann, Hernán González, José M Domínguez
Context. Radioiodine (RAI) administration has adverse effects in patients treated for thyroid cancer (DTC), but there is scarce information regarding their intensity and duration. Objective. To evaluate frequency and intensity of early and late RAI-related symptoms in patients with DTC. Design. Observational prospective study. Patients. DTC patients who underwent thyroidectomy, with or without RAI. Measurements. Patients answered 2 surveys: (1) from 0 to 6 months and (2) between 6 and 18 months after initial treatment...
2016: International Journal of Endocrinology
https://www.readbyqxmd.com/read/27856921/lenvatinib-a-multikinase-inhibitor-for-radioiodine-refractory-differentiated-thyroid-cancer
#17
REVIEW
Yvonne Hewett, Subash Ghimire, Bilal Farooqi, Binay K Shah
Lenvatinib, an oral multikinase inhibitor, was approved by the US Food and Drug Administration in February 2015. In a pivotal phase III study of 392 patients with progressive radioiodine-refractory thyroid cancer, the overall response rate of patients receiving lenvatinib was 64.8%, with complete response in four patients. The median progression-free survival was 18.3 months in the lenvatinib arm versus 3.6 months in patients receiving placebo. Median overall survival was not reached in either arm. Lenvatinib is a promising new treatment for patients with radioiodine (iodine-131)-refractory differentiated thyroid cancer...
November 17, 2016: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27853063/successful-re-administration-of-low-dose-of-methimazole-mmi-in-graves-disease-patients-who-experienced-allergic-cutaneous-reactions-to-mmi-at-initial-treatment-and-had-received-long-term-propylthiouracil-ptu
#18
Sumihisa Kubota
Objective When patients with Graves' disease show severe allergic cutaneous reactions, physicians often suggest that they undergo radioiodine therapy instead of receiving propylthiouracil (PTU), another antithyroid drug, because anti-neutrophil cytoplasmic antibody (ANCA) -related vasculitis can occur with PTU, especially with long-term use. However, some patients refuse radioiodine therapy and chose PTU. Sometimes PTU treatment may be prolonged. Since the frequency of adverse effects of methimazole (MMI) is dose-related, there is a possibility that we can re-administer a low dose without adverse effects to patients well-controlled with PTU who once experienced an allergic reaction to MMI...
2016: Internal Medicine
https://www.readbyqxmd.com/read/27848197/12-month-efficacy-of-a-single-radiofrequency-ablation-on-autonomously-functioning-thyroid-nodules
#19
Stella Bernardi, Fulvio Stacul, Andrea Michelli, Fabiola Giudici, Giulia Zuolo, Nicolò de Manzini, Chiara Dobrinja, Fabrizio Zanconati, Bruno Fabris
PURPOSE: Radiofrequency ablation has been advocated as an alternative to radioiodine and/or surgery for the treatment of autonomously functioning benign thyroid nodules. However, only a few studies have measured radiofrequency ablation efficacy on autonomously functioning benign thyroid nodules. The aim of this work was to evaluate the 12-month efficacy of a single session of radiofrequency ablation (performed with the moving shot technique) on solitary autonomously functioning benign thyroid nodules...
November 15, 2016: Endocrine
https://www.readbyqxmd.com/read/27845971/the-follicular-variant-of-papillary-thyroid-cancer-and-noninvasive-follicular-thyroid-neoplasm-with-papillary-like-nuclear-features-niftp
#20
Joseph Scharpf, Dipti Kamani, Peter M Sadow, Gregory W Randolph
PURPOSE OF REVIEW: Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) is a new terminology proposed for encapsulated follicular variant of papillary thyroid carcinoma (EFVPTC). Recently, thyroid cancer incidence has increased dramatically, without affecting related mortality rate. This increase is widely attributed to the intensified surveillance leading to a substantial increase in the diagnosis of small classic papillary thyroid cancers and EFVPTCs...
January 2017: Current Opinion in Oncology
keyword
keyword
20184
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"